Skip to content

Reviva Pharmaceuticals Holdings, Inc.: 10-Q filed 2022-08-15

What Reviva Pharmaceuticals Holdings, Inc. reported in its quarterly report filed 2022-08-15 (fiscal Q2 2022): 24 published measures, 72 facts as tagged in accession 0001437749-22-020538.

This filing

Form
10-Q (quarterly report)
Filed
2022-08-15
Fiscal period
fiscal Q2 2022
Accession
0001437749-22-020538 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Reviva Pharmaceuticals Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-06-3020,643,461USD
At 2021-12-3131,404,001USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-06-304,583,081USD
At 2021-12-312,717,541USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-06-3016,060,380USD
At 2022-03-3121,361,208USD
At 2021-12-3128,686,460USD
At 2021-06-3034,520,972USD
At 2021-03-314,516,450USD
At 2020-12-315,465,750USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-06-3019,420,062USD
At 2021-12-3129,687,944USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-5,340,704USD91
2022-01-01 to 2022-06-30-12,705,712USD181
2021-04-01 to 2021-06-30-1,608,407USD91
2021-01-01 to 2021-06-30-2,557,707USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-10,267,952USD181
2021-01-01 to 2021-06-30-4,456,984USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-06-3070USD181
2021-01-01 to 2021-06-3031,497,463USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-06-30-79,537,681USD
At 2021-12-31-66,831,969USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2022-04-01 to 2022-06-3018,466,586shares91
2022-01-01 to 2022-06-3018,466,586shares181
2021-04-01 to 2021-06-3012,874,961shares91
2021-01-01 to 2021-06-3010,961,449shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-0.29USD/shares91
2022-01-01 to 2022-06-30-0.69USD/shares181
2021-04-01 to 2021-06-30-0.12USD/shares91
2021-01-01 to 2021-06-30-0.23USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2022-04-01 to 2022-06-306,921USD91
2022-01-01 to 2022-06-3010,550USD181
2021-04-01 to 2021-06-303,902USD91
2021-01-01 to 2021-06-303,902USD181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-01-01 to 2022-06-3079,562USD181
2021-01-01 to 2021-06-3017,089USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-5,519,488USD91
2022-01-01 to 2022-06-30-12,969,645USD181
2021-04-01 to 2021-06-30-1,790,102USD91
2021-01-01 to 2021-06-30-3,663,030USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-06-304,477,382USD
At 2021-12-312,344,811USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-06-302,553,225USD
At 2021-12-31509,583USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-04-01 to 2022-06-305,519,488USD91
2022-01-01 to 2022-06-3012,969,645USD181
2021-04-01 to 2021-06-301,790,102USD91
2021-01-01 to 2021-06-303,663,030USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-04-01 to 2022-06-304,514,389USD91
2022-01-01 to 2022-06-3010,344,407USD181
2021-04-01 to 2021-06-30374,329USD91
2021-01-01 to 2021-06-30765,490USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-06-3014,433,286shares
At 2021-12-3114,433,286shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-06-3095,596,548USD
At 2021-12-3195,516,986USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2022-06-301,223,399USD
At 2021-12-311,716,057USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-5,333,783USD91
2022-01-01 to 2022-06-30-12,695,162USD181
2021-04-01 to 2021-06-30-1,604,505USD91
2021-01-01 to 2021-06-30-2,553,805USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-301,005,099USD91
2022-01-01 to 2022-06-302,625,238USD181
2021-04-01 to 2021-06-301,415,773USD91
2021-01-01 to 2021-06-302,897,540USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2022-04-01 to 2022-06-30185,705USD91
2022-01-01 to 2022-06-30274,483USD181
2021-04-01 to 2021-06-30185,597USD91
2021-01-01 to 2021-06-301,109,225USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-06-301,874,328USD181
2021-01-01 to 2021-06-30-649,789USD181

Inspect the source

Entity
Reviva Pharmaceuticals Holdings, Inc. / CIK 0001742927
Captured
2026-09-19T11:20:56.685Z
SEC response SHA-256
26f740ff1a169faebcba46f28197dc15a1be7bab2feb9b4952e7b7f15df066e6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001742927.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))